8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  September 3, 2015

Echo Therapeutics, Inc.

 (Exact name of Company as specified in its charter)

Delaware	001-35218	41-1649949
(State or other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
99 Wood Avenue South., Suite 302 Iselin, NJ		08830
(Address of principal executive offices)		(Zip Code)

Company’s telephone number, including area code: (732) 549-0128

 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.03 Amendments to Articles of Incorporation or Bylaws, Change in Fiscal Year.

On September 3, 2015, Echo Therapeutics, Inc. (the “Company”) filed a Certificate of Increase of Shares Designated as Series F Convertible Preferred Stock (“Certificate of Increase”) with the Secretary of State of the State of Delaware to increase the number of shares designated as its Series F Preferred Stock from 5,000,000 to 6,000,000 shares.  The Certificate of Increase is attached hereto as Exhibit 3.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
3.1	Certificate of Increase of Shares Designated as Series F Convertible Preferred Stock of Echo Therapeutics, Inc.

SIGNATURES

              Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ECHO THERAPEUTICS, INC.
Dated: September 9, 2015	By: /s/ Alan W. Schoenbart
	Alan W. Schoenbart
	Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
3.1	Certificate of Increase of Shares Designated as Series F Convertible Preferred Stock of Echo Therapeutics, Inc.

EX-3.1

Exhibit 3.1

CERTIFICATE OF INCREASE

OF

SHARES DESIGNATED

AS

SERIES F CONVERTIBLE PREFERRED STOCK

OF

ECHO THERAPEUTICS, INC.

(Pursuant to Section 151 of the Delaware General Corporation Law)

*  *  *  *  *

Echo Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify:

FIRST: That the Certificate of the Designation, Preferences and Rights of Series F Convertible Preferred Stock of Echo Therapeutics, Inc. was filed in the office of the Secretary of State of the State of Delaware on December 22, 2014.

SECOND: The Board of Directors of the Corporation, by the unanimous written consent of its members dated August 28, 2015 filed with the minutes of the Board, duly adopted resolutions authorizing and directing an increase in the number of shares designated as Series F convertible preferred of the Corporation, from 5,000,000 shares to 6,000,000 shares, in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this Certificate to be signed by its duly authorized offer this 28th day of August, 2015.

ECHO THERAPEUTICS, INC.

By  /s/ Alan Schoenbart

Alan Schoenbart,

Chief Financial Officer